CA
NZ
UK
AU
IND
US
Two things happened inside two weeks that changed how Johnson & Johnson (NYSE:JNJ) is being framed. First, second-quarter results in mid-July came with raised full-year 2026 guidance: reported sales of $100.8bn to $101.4bn, up from $100.3bn to $101.3bn, with adjustedEarnings Per Sharelifted to $11.60–$11.75 …
Krystal Biotech (Nasdaq:KRYS) closed at $341.12 on Friday, down 7.01%, or $25.73, on volume of 488,157 shares. The company published no news that day. Its only July announcement was the routine 23 July notice that second-quarter results would be released on 3 August, and …
Wetouch Technology Inc. (NASDAQ: WETH) has secured $38,797,287.50 by issuing 31,037,830 shares of common stock priced at $1.25 each. The transaction represents approximately 8% of the company’s $16 million marketCapitalization, providing essential funds to advance touch-screen technology development and acquisitions.
Gilead Sciences (Nasdaq:GILD) enters August with the densest regulatory calendar it has faced in years and a share price well below its 2026 peak. The FDA's target action date for bictegravir plus lenacapavir, a once-daily single-tablet regimen for adults already virologically suppressed, is, following …
Xometry, Inc. has appointed Sanjeev Singh Sahni as its new Chief Executive Officer, introducing substantial changes to his severance package. Under the new arrangement, Sahni would be eligible for severance benefits amounting to 150% of his target annual performance bonus. This shift comes at …
Globus Medical (NYSE:GMED) closed at $78.79 at last closing, down 1.83% on the session, according to aggregated market data's price history. That leaves the shares roughly 22% below the $101.40 high of the past 52 weeks, even though the company has beaten and raised …
Guardant Health (Nasdaq:GH) closed at $161.99, up 6.33% on the day, after reporting second-quarter revenue of $335.0 million, 44% above the prior year, and lifting full-year guidance for the second time in 2026. Guidance rose to $1.34–$1.36 billion from $1.30–$1.32 billion, implying 36% to …
IDEXX Laboratories (Nasdaq:IDXX) closed at $559.07 on Friday, up 0.05% on the day, a move small enough to round to nothing, three sessions before the veterinary diagnostics company reports second-quarter results. The company confirmed on 1 July that the release arrives before the market …
Illumina (Nasdaq:ILMN) used its July 30 second-quarter report to do something it has rarely managed this decade: raise the year. Revenue of $1.16 billion rose 9.5% against Q2 2025, and 8.1% excluding currency, acquisitions and China. Non-GAAP diluted earnings of $1.31 a share came …
Incyte (Nasdaq:INCY) reported second-quarter results on 28 July. Total revenues reached $1.67 billion, up 38% year over year, and management lifted full-year net product sales guidance to $5.13–$5.26 billion from $4.77–$4.94 billion. "Our second quarter was marked by broad-based sales growth, continued pipeline progress …
Please wait processing your request...